A novel immunocytokine termed as BIPI was generated by fusing hIL-2 to the C-Term of atezolizumab.
It was effective in stimulating T cell activation and could selectively localize to the tumor.
Tumor regression and prolonged survival were observed in metastatic colorectal cancer mouse model.
BIPI induced the IFN-γ secretion in the spleen of mice.
BIPI has the potential to treat cancers with a low response to anti-PD-L1 antibody or IL-2 treatment.